×
Nutriband Common Stock Net 2016-2025 | NTRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Nutriband common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Nutriband Common Stock Net 2016-2025 | NTRB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Nutriband common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$68.7B
Zoetis (ZTS)
$66.4B
Takeda Pharmaceutical (TAK)
$46.6B
Daiichi Sankyo, - (DSNKY)
$46.2B
BeOne Medicines - (ONC)
$31.6B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$19.1B
Merck (MKKGY)
$16.9B
Shionogi (SGIOY)
$15.4B
United Therapeutics (UTHR)
$13.6B
Neurocrine Biosciences (NBIX)
$12.8B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.4B
Madrigal Pharmaceuticals (MDGL)
$8B
Corcept Therapeutics (CORT)
$7.8B
Grifols, S.A (GRFS)
$7.3B
Stevanato Group S.p.A (STVN)
$6.6B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.3B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.4B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.8B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Hypermarcas (HYPMY)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B